Showing results (141-150 of 219) with videos related to

Sort By:
Pageof 22
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 1, 2019
[Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes]H J Huang, Z X Shi, B Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 25, 2018
[Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing]B Li, J Y Wang, J Q Liu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 3, 2025
[Clinical and molecular characteristics of myeloproliferative neoplasms patients with NFE2 gene mutations]S Y Zhao, B Li, Z F Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|February 2, 2019
[A study of clinical characteristics and prognosis of primary myelofibrosis patients with thrombocytopenia in varied degrees]Z F Xu, T J Qin, H L Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 19, 2016
[Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis]Z F Xu, B Li, J Q Liu, et al.
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.
Frontiers in Pharmacology|July 4, 2017
<i>N</i>-Desmethyldauricine Induces Autophagic Cell Death in Apoptosis-Defective Cells via Ca<sup>2+</sup> MobilizationBetty Y K Law, Simon W F Mok, Juan Chen, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 6, 2026
[Clinical characteristics and prognosis of myelodysplastic neoplasms with GATA2 mutations]J Tang, Y J Jia, T J Qin, et al.
Clinical Genitourinary Cancer|December 3, 2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Pageof 22